Pfizer and Arvinas are poised to bring the third oral selective oestrogen receptor degrader (SERD) to market in the US, after ...
The incidence of allergic diseases has dramatically increased in the last decades. The dysregulation of our immune systems ...
Hosted on MSN
Pfizer lags as Cadrenal advances to Phase 3 trial
Pfizer shares remain under pressure amid declining COVID vaccine demand, looming patent expirations, and delays in entering the GLP-1 weight-loss market. Meanwhile, Cadrenal Therapeutics gained ...
StockStory.org on MSN
Pfizer earnings: What to look for from PFE
Global pharmaceutical company Pfizer (NYSE:PFE) will be reporting results this Tuesday before the bell. Here’s what investors ...
Pfizer is facing headwinds today, which is why investors seem to be ignoring the stock. The giant pharmaceutical company is ...
S&P 500 Q1 earnings surge 27.1% as Alphabet, Apple, Amazon beat forecasts. Meta falls on AI capex fears. 128 firms report ...
Pfizer Inc. (NYSE:PFE) ranks among the best low-risk investments in May 2026. On April 13, Guggenheim reaffirmed a Buy rating ...
The U.S. Food and Drug Administration on Friday approved Pfizer and Arvinas' breast cancer drug for patients with an ...
Known as Veppanu, the drug is the first of its kind to get to market. But Arvinas and partner Pfizer are still searching for ...
Pfizer and Arvinas' Veppanu Gets FDA OK Alongside Guardant Health CDx for ESR1-Mutated Breast Cancer
The agency's decision was based on data from the VERITAC-2 trial, which showed Veppanu improved progression-free survival by nearly three months over fulvestrant.
Arvinas and Pfizer are the first to take a PROteolysis TArgeting Chimera (PROTAC) therapy across the FDA finish line, opening ...
This week in Other Barks & Bites: the U.S. Trade Representative issues its annual Special 301 Report listing the European ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results